|Bid||25.50 x 0|
|Ask||26.00 x 0|
|Day's range||25.05 - 25.50|
|52-week range||17.75 - 40.50|
|Beta (5Y monthly)||1.48|
|PE ratio (TTM)||63.12|
|Earnings date||23 Sept 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||59.00|
If you want to know who really controls Allergy Therapeutics plc ( LON:AGY ), then you'll have to look at the makeup of...
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL Primary endpoint Combined Symptom Medication Score (CSMS) achieved with clinically relevant improvement across both active treatment groups compared to placebo Statistically significant reduction in CSMS seen in both active treatment groups of 29.1% and 36.8% compared to placebo Analysis